New candidate genes for ST-elevation myocardial infarction.

Area of Science:

• Cardiovascular Biology
• Molecular Genetics
• Thrombosis Research

Background:

• Mechanisms of coronary atherothrombosis in ST-elevation myocardial infarction (STEMI) remain unclear despite extensive atherosclerosis research.
• Investigating leukocyte gene expression in STEMI patients can elucidate underlying causes of coronary atherothrombosis.
• Distinguishing primary gene expression changes from secondary inflammation is crucial for understanding STEMI pathogenesis.

Purpose of the Study:

• To identify candidate genes involved in STEMI by analyzing leukocyte gene expression.
• To differentiate primary genetic factors from secondary inflammatory responses in STEMI.
• To uncover novel molecular targets for STEMI treatment and prevention.

Main Methods:

• Gene expression analysis of leukocytes from 51 STEMI patients at acute phase (P1), 24-48h (P2), and 3 months (P3).
• Utilized Affymetrix Human Transcriptome Array 2.0 for comprehensive gene expression profiling.
• Excluded secondary inflammatory gene expression changes by comparing P1 to P3 (convalescent) samples, focusing on genes differentially expressed in P1.

Main Results:

• Identified seven genes differentially expressed in the acute phase of STEMI compared to convalescence.
• Three genes (ABCG1, RAB20, TMEM2) were upregulated, and four genes (ACVR1, NFATC2IP, SUN1, TTC9C) were downregulated in STEMI patients.
• These seven candidate genes were also found to be highly expressed in carotid atherosclerotic plaques, suggesting a role in atherosclerosis.

Conclusions:

• Seven candidate genes were identified as potentially involved in the mechanisms of STEMI.
• The study's unique approach excluded secondary inflammatory responses, providing a clearer view of primary genetic involvement.
• Further studies are needed to replicate these findings and validate the role of these genes in STEMI pathogenesis.